Product Information
FLUTICASONE-SALMETEROL 100-50 is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.0736 per EA under NDC 00093751731. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Dec 13, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100; 50 ug/1; ug/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093751731
Classification
Generic
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Generic (ANDA)
FDA Application
ANDA213948FDA Approved
12/13/2021
TE Code
AB
On Market Since
3/23/2022
Pharmacological Classes
Price Statistics
The NADAC for FLUTICASONE-SALMETEROL 100-50 has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 35.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0736 per EA |
|---|---|
| All-time high | $1.6569 (Jun 15, 2022) |
| All-time low | $0.8022 (May 22, 2024) |
| 52-week high | $1.1724 |
| 52-week low | $1.0736 |
| Median price | $1.2134 |
| Average price | $1.2215 |
| Largest weekly change | +53.1% (Jun 19, 2024) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone propionate and salmeterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLUTICASONE-SALMETEROL 100-50?
The current National Average Drug Acquisition Cost (NADAC) for FLUTICASONE-SALMETEROL 100-50, manufactured by Teva Pharmaceuticals USA Inc., is $1.0736 per EA (NDC 00093751731), effective Sep 30, 2026.
How has the price of FLUTICASONE-SALMETEROL 100-50 changed over time?
Over the history we have for it, the NADAC for FLUTICASONE-SALMETEROL 100-50 has declined 35.2%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for FLUTICASONE-SALMETEROL 100-50?
Since Jun 1, 2022, the NADAC for FLUTICASONE-SALMETEROL 100-50 has ranged from a low of $0.8022 (May 22, 2024) to a high of $1.6569 (Jun 15, 2022), with a median of $1.2134 per EA.
Are there cheaper alternatives to FLUTICASONE-SALMETEROL 100-50?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FLUTICASONE-SALMETEROL 100-50 in a comparable dosage form, but none are currently priced below it.
Who manufactures FLUTICASONE-SALMETEROL 100-50?
FLUTICASONE-SALMETEROL 100-50 (NDC 00093751731) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.